Bengaluru-based global pharma maker of generic medicines across the US, Europe, Africa and emerging markets.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 583 | +16.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 10.0 | −3.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 73.0 | +461.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 20.48 | +15.7 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 5.99 | −5.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 8.05 | −10.9 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Guidance
2 of 2 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Gross Margin | 58% to 60% is a good range for us to remain in | Q1 FY26 | Achieved 60.9%, exceeding the guided 58-60% range. Commitment to the range reiterated. | Achieved |
| US Revenue Target | $400 million objective... next 2 years | Q4 FY25 | Reiterated aspiration of '$375 million North America business by FY28'. Q1 US revenue at $68M. | On Track |
10 of Strides Pharma Science Limited's 12 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 10 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹814.55 on 24 Oct 2025 → ₹1,033.1. High ₹1,235.1 (21 Sept 2026), low ₹793.55 (27 Jan 2026).
Overview
Based on the company's own presentations, annual report and earnings calls.
Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company that develops, manufactures and markets generic finished-dosage medicines. It earns revenue through a direct commercial business in the US and Other Regulated Markets (UK, Nordics, Australia), an emerging-markets Growth business spanning Africa and expanding into LATAM, MENA and APAC, and a separate institutional business that supplies donor-funded and tender-based Access Markets. The company runs manufacturing operations in India (Bengaluru, Puducherry and the Chennai/Alathur region), Italy (Milan) and Kenya (Nairobi), with a commercial presence in the US (New York). Its pipeline is expanding into complex generics such as nasal sprays, transdermal patches and films alongside its established portfolio of commercialized generic products.
Segments
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
2 of 2 judged targets kept · 10 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Gross Margin | 58% to 60% is a good range for us to remain in | Q1 FY26 | Achieved 60.9%, exceeding the guided 58-60% range. Commitment to the range reiterated. | Achieved |
| US Revenue Target | $400 million objective... next 2 years | Q4 FY25 | Reiterated aspiration of '$375 million North America business by FY28'. Q1 US revenue at $68M. | On Track |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 12 tracked commitments, with each call’s wording and source.
Call summaries
Strides Pharma Science Limited Q1 FY27
Strides Pharma Science Limited reported a steady Q1 FY27 with 13% YoY topline growth, driven by strong Ex-US performance. The company maintained healthy gross and EBITDA margins despite geopolitical and inflationary pressures, while also reducing net debt. Strategic focus remains on niche US domains and expanding Ex-US markets, with key product approvals and acquisitions expected in H2.
Read the full callStrides Pharma Q4 FY26
Strides Pharma delivered strong financial performance in FY26, with a 12% CAGR in revenue and 26% CAGR in EBITDA over the last three years, driven by geographical diversification and improved profitability. While FY26 revenue growth was 6.4% due to a weak U.S. flu season and access market challenges, the company achieved its highest-ever EBITDA margin of 19% and an 18x growth in operational PAT over three years. Investments in R&D and strategic partnerships are expected to drive future growth, particularly in Ex-U.S. markets, with a focus on maintaining strong margins and a resilient balance s
Read the full callStrides Pharma Q3 FY26
Strides Pharma reported a strong Q3 FY26, driven by robust profitability and significant growth in Ex-U.S. markets, which now contribute 47% of revenues and grew 20% YoY. Gross margins exceeded 60%, and EBITDA reached a record Rs. 236 crores, up 12% YoY. The company also improved its debt/EBITDA ratio to 1.59x and ROCE to 15.8%, despite flat U.S. revenue due to seasonal factors and product discontinuations.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
Net profit, year on year: +462% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 520 | 551 | 556 | 499 | 522 | 554 | 606 | 583 |
| Expenses | 464 | 477 | 488 | 431 | 460 | 472 | 531 | 522 |
| Operating profit | 55 | 74 | 68 | 67 | 62 | 81 | 74 | 61 |
| Operating margin | 11.0% | 13.0% | 12.0% | 13.0% | 12.0% | 15.0% | 12.0% | 10.0% |
| Other income | 24 | 2 | 12 | 2 | 14 | 103 | 4 | 78 |
| Interest | 42 | 34 | 29 | 30 | 29 | 27 | 27 | 29 |
| Depreciation | 21 | 21 | 22 | 22 | 22 | 22 | 25 | 26 |
| Profit before tax | 16 | 21 | 28 | 16 | 25 | 135 | 27 | 85 |
| Tax rate | −5.0% | 30.0% | 43.0% | 19.0% | −26.0% | 10.0% | 38.0% | 14.0% |
| Net profit | 17 | 15 | 16 | 13 | 32 | 122 | 16 | 73 |
| EPS (₹ per share) | 1.88 | 1.62 | 1.75 | 1.45 | 3.48 | 13.23 | 1.77 | 7.91 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 3,688 | 2,011 | 2,213 | 2,181 |
| Expenses | 3,543 | 1,804 | 1,949 | 1,894 |
| Operating profit | 145 | 206 | 263 | 284 |
| Other income | 93 | 90 | 46 | 123 |
| Interest | 262 | 154 | 153 | 113 |
| Depreciation | 243 | 88 | 86 | 91 |
| Profit before tax | -268 | 54 | 69 | 203 |
| Net profit | -212 | 53 | 50 | 183 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 90 | 90 | 92 | 92 | 92 | 92 |
| Reserves | 3,317 | 3,365 | 3,436 | 3,101 | 2,664 | 3,191 |
| Borrowings | 1,284 | 1,414 | 1,688 | 1,202 | 1,844 | 1,184 |
| Other liabilities | 743 | 750 | 687 | 636 | 1,921 | 928 |
| Total liabilities | 5,434 | 5,620 | 5,902 | 5,031 | 6,521 | 5,396 |
| Fixed assets | 617 | 597 | 747 | 767 | 2,139 | 785 |
| Capital work in progress | 56 | 55 | 107 | 106 | 164 | 181 |
| Investments | 2,400 | 2,492 | 2,364 | 1,848 | 440 | 1,868 |
| Other assets | 2,361 | 2,476 | 2,684 | 2,311 | 3,777 | 2,561 |
| Total assets | 5,434 | 5,620 | 5,902 | 5,031 | 6,521 | 5,396 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 283 | -283 | 242 | -14 | 421 | 278 |
| Cash from investing | -276 | 19 | -183 | -69 | -138 | -69 |
| Cash from financing | -49 | 251 | 11 | 93 | -370 | -199 |
| Net cash flow | -42 | -13 | 70 | 11 | -86 | 10 |
| Free cash flow | 196 | -350 | 161 | -89 | 264 | 116 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 161 | 239 | 257 | 306 | 248 | 255 |
| Inventory days | 254 | 170 | 168 | 188 | 145 | 191 |
| Days payable | 271 | 213 | 220 | 205 | 163 | 225 |
| Cash conversion cycle | 144 | 196 | 205 | 289 | 230 | 220 |
| Working capital days | 16 | 22 | 48 | 41 | 83 | 83 |
| Return on capital employed | 4.0% | 2.0% | 2.0% | 2.0% | 5.0% | 5.0% |
| Dividend payout | 29.0% | 0.0% | 289.0% | 52.0% | 1.0% | 25.0% |
The businesses behind the company’s reported revenue.
Pharmaceutical business contributes 100.0% of reported segment revenue.
Quarter ended 30 Sept 2024 · Consolidated
₹1,201.11 crore
₹0.00 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Pharmaceutical business | 1,201.11 | 100.0% |
| Bio-pharmaceutical business | 0.00 | 0.0% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
Each segment’s share of reported revenue, quarter by quarter.
| Segment | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | YoY growth latest quarter |
|---|---|---|---|---|---|---|
| Pharmaceutical business | 100% | 100% | 100% | — | 100% | +20.2% |
| Bio-pharmaceutical business | 0% | 0% | 0% | — | 0% | — |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
Ownership
Promoters hold 29.00% as of Sept 2026; institutions cut 0.33 pts since Jun 2026.
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 1 holder trimming and 2 off the list — both are in the register beside this.
Named in the Sep 2026 filing
Every holder of Strides Pharma Science Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 19.62% | unchanged | |
| Mutual fund | 6.18% | newly disclosed |
| FPI fund | 5.05% | unchanged |
| 3.50% | unchanged | |
| Insurer | 3.47% | −1.29 pp |
| 3.10% | +1.08 pp | |
| 2.79% | newly disclosed | |
| FPI fund | 2.17% | unchanged |
| 1.60% | unchanged | |
| Sovereign | 1.46% | +0.13 pp |
| 1.36% | unchanged | |
| NBFC / DFI | 1.34% | +0.06 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Strides Pharma Science Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.